UMich logo

PettitKristen headshot 2018Principal Investigator: Dr. Kristen Pettit

Disease: Myelofibrosis

Research Description: Myelofibrosis (MF) is a rare, aggressive bone marrow cancer causing excessive scar tissue or fibrosis to form in the blood marrow, resulting in bone marrow failure, massively enlarged spleen, significant symptoms and impaired quality of life for patients. Ruxolitinib is the only approved drug available to treat MF, and this treatment improves symptoms for about half of patients. For those who do not respond or eventually develop resistance, there is no second-line treatment option. Dr. Pettit and her team believe that trametinib, a drug currently approved to treat melanoma, may help overcome this resistance and at the same time may improve fibrosis.  They plan to conduct a clinical trial combining trametinib with ruxolitinib for patients whose MF has progressed on ruxolitinib alone. This study will test the safety of using these two drugs in combination for MF, and will identify the optimal dose of trametinib to use in this combination.

CWR Funding Role: Participating funder

CWR Fuding Partner: Goldman Philanthropic Partnerships

CWR Funding Start Date: December 2018

Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*

*required

If the link above doesn't work, please email susan@cureswithinreach.org with your Full Name and Email Address to sign up!

 

Cures Within Reach

134 N. LaSalle, #1130
Chicago, IL 60602

info@cureswithinreach.org

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes. 

Partnership for Cures DBA Cures Within Reach is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.

 

Sunday the 16th. Copyright 2018 Cures Within Reach.